Photodynamic Therapy With Hydrogel Dressing for Chronic Wounds

Launched by ARMY MEDICAL UNIVERSITY, CHINA · Jun 4, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a treatment called photodynamic therapy (PDT) combined with a special hydrogel dressing to help heal chronic wounds that have not responded to standard treatments for at least three months. The study involves 63 patients with long-lasting wounds, and they are divided into three groups. One group will receive only the hydrogel dressing, another will get PDT treatment, and the third group will receive both PDT and the hydrogel dressing. Researchers will assess how well the wounds heal, how satisfied patients are with their treatment, and if there are any side effects or problems after the treatment.

To be eligible for this trial, participants must have a chronic wound caused by trauma or surgery, and their wound should be less than 10 centimeters in diameter. They also need to be generally healthy and not taking certain medications that could affect the treatment. Participants can expect to participate in a structured treatment plan and will receive regular follow-ups to monitor their progress. This trial is an opportunity for individuals with difficult-to-heal wounds to potentially benefit from a new treatment approach while contributing to important medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1) patients with chronic wounds caused by trauma or surgery who failed to heal after traditional formal medical treatment at least over three months;
• • 2) Patients with stable vital signs who had no systemic medical disease and did not take glucocorticoids, immunosuppressive agents, or anticoagulants during the entire treatment process;
• • 3) Participants provided signed informed consent, were able to comply with the program, were willing to participate in follow-up, and were able to cooperate in the observation of adverse events and efficacy;
• • 4) The diameter of the skin wound should not exceed 10 centimeters.
• Exclusion Criteria:
• • 1) Patients are allergic to ALA;
• • 2) Women with recent fertility, pregnancy or lactation plans;
• • 3) Patients with deepening wounds or worsening infections;
• • 4) Poor compliance leading to an inability to complete the treatment in its entirety;
• • 5) Cutaneous ulcer caused by vascular disease, autoimmune diseases, metabolic diseases, local or metastatic malignant tumors.

Trial Officials